As the Q1 earnings season comes to a close, it’s time to take stock of this quarter’s best and worst performers in the ...

After soaring in early pandemic days, Moderna has fallen into the doldrums. An explosive phase of growth may be ahead thanks ...

Moderna stock has faced heavy pressure from negative headlines, regulatory setbacks and political uncertainty. See why I ...

Moderna's (NASDAQ: MRNA) sales are slowing down, and Moderna stock is going down -- a lot. The coronavirus vaccine maker's shares plunged 21.2% through 10:20 a.m. ET Monday after it updated ...

Moderna probably won't go down in history as a one-hit wonder, however. The biotech has a rich and diverse pipeline of candidates that could fuel a recovery in its stock performance.

Moderna (NASDAQ: MRNA) was the top-performing stock in the S&P 500 not too long ago when the company joined the index in mid-2021. At its peak in 2021, the company's value soared to $187 billion ...

Many investors still see Moderna as a coronavirus stock and have questioned growth prospects. The main bull case for Moderna is that it's poised to return to growth soon. But as vaccine demand ...

Moderna stock rallied 9% yesterday, after it launched phase 2/phase 3 clinical trials for a messenger RNA-based vaccine for skin cancer patients that it is developing with Merck. As per an earlier ...

And though share performance has cooled in recent times, the stock still has put a smile on the faces of long-term investors, climbing almost 400% over the past three years.

Moderna stock declined by about 30% over the last week (five trading days) following the company’s weaker than expected Q3 2021 results. While Moderna’s revenue for Q3 grew by almost 13% ...